The "Insight" Trial: Two New Strata Of An Explorative, Open-Labeled Phase I Study Evaluating The Feasibility And Safety Of Subcutaneous Imp321 Injections (Lag-3ig Fusion Protein, Eftilagimod Alpha) Combined With Either Standard-Of-Care Drug Therapy Or Pd-L1 Inhibition (Avelumab) In Advanced-Stage Solid Tumor Entities.